390 related articles for article (PubMed ID: 21161300)
1. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
2. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
3. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
4. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
Kupershmidt L; Youdim MBH
Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
[TBL] [Abstract][Full Text] [Related]
5. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
7. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
8. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
10. The role of iron in brain ageing and neurodegenerative disorders.
Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
[TBL] [Abstract][Full Text] [Related]
11. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
12. The potential application of iron chelators for the treatment of neurodegenerative diseases.
Hider RC; Roy S; Ma YM; Le Kong X; Preston J
Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
[TBL] [Abstract][Full Text] [Related]
13. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
[TBL] [Abstract][Full Text] [Related]
15. Iron and Parkinson's disease: chelators to the rescue?
Levenson CW
Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina.
Shahandeh A; Bui BV; Finkelstein DI; Nguyen CTO
J Neurosci Res; 2020 Oct; 98(10):1889-1904. PubMed ID: 32643793
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic new insights of flavonols on neurodegenerative diseases.
Tahir MS; Almezgagi M; Zhang Y; Bashir A; Abdullah HM; Gamah M; Wang X; Zhu Q; Shen X; Ma Q; Ali M; Solangi ZA; Malik WS; Zhang W
Biomed Pharmacother; 2021 May; 137():111253. PubMed ID: 33545661
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation in the treatment of neurodegenerative diseases.
Dusek P; Schneider SA; Aaseth J
J Trace Elem Med Biol; 2016 Dec; 38():81-92. PubMed ID: 27033472
[TBL] [Abstract][Full Text] [Related]
19. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
[TBL] [Abstract][Full Text] [Related]
20. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
Singh YP; Pandey A; Vishwakarma S; Modi G
Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
